Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of BDB-001 in progressive severe COVID-19
2020-001671-32Phase 2Terminated
- Sponsor
- Staidson Biopharmaceutical
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BDB-001 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Staidson Biopharmaceutical. Primary endpoint: Recovery rate. Started May 2020; status: terminated.
02
Drugs
BDB-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001671-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001671-32.